HCW Biologics announced that its previously issued financial statements for the first quarter ended March 31, 2026, should no longer be relied upon due to a significant error in its earnings per share (EPS) calculation. The company plans to file an amended quarterly report to restate the affected financial results.
Key Details
- Accounting Error: The company misapplied the two-class method for calculating EPS, failing to correctly allocate undistributed earnings between Common Stock and participating securities.
- Financial Impact: This error resulted in an overstatement of basic and diluted EPS for Q1 2026. The reported EPS of $2.19 was overstated by $0.80 per share.
- Internal Controls: Management concluded that a material weakness existed in its internal control over financial reporting related to technical accounting review and is implementing remediation measures.